Role of Mitogen-activated protein kinase kinase kinase kinase 4 signaling in liver and metabolic diseases.
Liver
MAP Kinase
liver disease
Journal
The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
accepted:
28
05
2024
received:
04
01
2024
revised:
17
05
2024
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
6
6
2024
Statut:
aheadofprint
Résumé
MAP4K4 is a serine/threonine protein kinase belonging to the germinal center kinase (GCK) sub-group of sterile 20 protein (Ste20p) family of kinases. MAP4K4 has been involved in regulating multiple biological processes and a plethora of pathologies, including systemic inflammation, cardiovascular diseases, cancers, metabolic and hepatic diseases. Recently, multiple reports have indicated the upregulation of MAP4K4 expression and signaling in hyperglycemia and liver diseases. This review summarizes our current understanding of MAP4K4 structure, expression, as well as its regulation and signaling, specifically in metabolic and hepatic diseases. Reviewing these promising studies will enrich our understanding of MAP4K4 signaling which will help us design innovative therapeutic interventions against metabolic and liver diseases using MAP4K4 as a target.
Identifiants
pubmed: 38844365
pii: jpet.124.002065
doi: 10.1124/jpet.124.002065
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 American Society for Pharmacology and Experimental Therapeutics.